The HART (HPV in Addition to Routine Testing) study suggests that screening women for human papillomavirus and then triaging those who are positive with cytology may improve detection rates of high-grade cervical intraepithelial neoplasia (CIN2+) without increasing the rate of colposcopies.
HART was a British multicenter screening study involving more than 11,000 women between 30 and 60 years of age from 161 family practices. The researchers randomized women with borderline cytology and women positive for high-risk HPV with negative cytology to receive either immediate colposcopy or repeat HPV testing, cytology, and colposcopy in 12 months.
In terms of detecting CIN2+, the authors found HPV testing to be considerably more sensitive than borderline or worse cytology (97.1% vs. 76.6%, respectively), and only slightly less specific (93.3% vs. 95.8%). They also found 12-month surveillance of HPV-positive women with negative or borderline cytology to be as effective as immediate colposcopy.
In addition, they determined that HPV testing is more sensitive than cytology in detecting atypical squamous cells of undetermined significance, and that it has the potential to reduce the rate of colposcopy referrals for mild dyskaryosis.1
An accompanying editorial in the same issue of the Lancet points out that while Pap cytology screening has successfully cut the incidence of cervical cancer by about 75%, Pap testing has a sensitivity of only about 51% and a high false-negative rate. The author also explains that the concept of serial diagnostic testing (with first a highly sensitive test followed by a highly specific one to triage) has good precedent in other areas of medicine, such as testing for syphilis. And finally, he supports shifting the focus of screening from a morphology-based approach to one that searches for the sexually transmitted cause, remarking that placing "the emphasis of prevention not only on women but on their partners as well" is long overdue.2
1. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
2. Franco EL. Are we ready for a paradigm change in cervical cancer screening? Lancet. 2003;362:1866-1867.
Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation
April 22nd 2024A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.
Read More
Personalized opioid protocol for cesarean deliveries: Reduced prescriptions reported
April 19th 2024A recent suggests that implementing a personalized opioid prescription protocol significantly reduces total morphine milligram equivalents and the number of opioid tablets prescribed at discharge following cesarean delivery.
Read More
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More